Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PKC Inhibitor
N-Myristoyl-Lys-Arg-Thr-Leu-Arg is a selective inhibitor of protein kinase C (PKC), exhibiting an IC50 of 75 μM. This compound effectively inhibits the induction of the IL-2 receptor and production of IL-2 in the Jurkat human leukemic cell line. It can be utilized in research focused on understanding PKC-related signaling pathways and their role in immune responses. -
PKC-θ Inhibitor
PKC-theta inhibitor 2 hydrochloride is a highly selective inhibitor of protein kinase C theta (PKC-θ), exhibiting an IC50 of 18 nM. This compound modulates key signaling pathways associated with T cell activation and proliferation. It serves as a valuable tool in research investigating autoimmune diseases, cancer therapeutics, and immune response modulation. -
PKC Inhibitor
Safingol is a lyso-sphingolipid that acts as a selective protein kinase C (PKC) inhibitor. It has demonstrated potential in modulating various cellular signaling pathways, making it an important tool in cancer research and studies of cell survival and apoptosis. Safingol is valuable for investigating the role of PKC in diseases and may aid in the development of therapeutic strategies targeting this kinase. -
OPN4 Inhibitor
AE 51310 is an inhibitor of the OPN4 receptor, effectively disrupting the activation of protein kinase C (PKC) and the downstream BRAF/MEK/ERK signaling cascade. This compound is valuable for cancer research, particularly in the study of non-small cell lung cancer (NSCLC). Its ability to modulate critical signaling pathways makes AE 51310 a useful tool in investigating tumor biology and potential therapeutic targets. -
PKC-ι Inhibitor
PKCiota-IN-1 is a potent inhibitor of protein kinase C iota (PKC-ι) with an IC50 of 2.7 nM. This compound also exhibits inhibitory activity against PKC-α and PKC-ε, with IC50 values of 45 nM and 450 nM, respectively. PKCiota-IN-1 is valuable for studying the role of PKC-ι in various biological processes and has potential applications in cancer research and therapeutic strategies targeting PKC pathways. -
PKC Inhibitor
CIDD-0072424 is a selective inhibitor of Protein Kinase C-epsilon (PKCε), exhibiting an inhibitory constant (Ki) of 54 nM. This compound has been shown to reduce ethanol consumption and preference in a dose-dependent manner, making it a valuable tool for studying alcohol-related behaviors and signaling pathways. It is applicable in research investigating the role of PKCε in addiction and other neurobiological processes. -
PKC Inhibitor
MT477 is a potent protein kinase C (PKC) inhibitor that induces both apoptosis and necrosis in target cells. This compound effectively reduces the protein expression levels of Ras-GTP, p-Erk1/2, and p-Elk1. Due to its mechanism of action, MT477 demonstrates significant antitumor activity, making it a valuable tool for cancer research and therapeutic investigations. -
PKC Inhibitor
PKC-IN-5, a protein kinase C (PKC) inhibitor, disrupts the interaction between PKC epsilon (PKCe) and its adaptor protein RACK2. This inhibition can modulate PKC-mediated signaling pathways, making PKC-IN-5 a valuable tool for studying PKC-related cellular processes. Its application extends to research in cancer biology and neurodegenerative diseases, where PKC signaling plays a critical role. -
Protein Kinase C Inhibitor
Ro 31-8830 is a potent and selective inhibitor of protein kinase C, which plays a crucial role in various cell signaling pathways. This compound demonstrates anti-inflammatory activity and is valuable for research focused on inflammatory disorders. Its capabilities make Ro 31-8830 a significant tool for investigating the mechanisms underlying inflammation and evaluating potential therapeutic strategies. -
PKC Inhibitor
R8605 is a protein kinase C (PKC) inhibitor with a reported IC50 of 65 μM in the rat brain. This compound also inhibits calcium/phospholipid-independent phosphorylation of protamine, with IC50 values of 70 μM and 100 μM, respectively. R8605 is applicable in cancer research, facilitating studies on PKC-mediated signaling pathways and their implications in tumorigenesis. -
PKC Inhibitor
Safingol hydrochloride is a lyso-sphingolipid that functions as a potent inhibitor of protein kinase C (PKC). This compound exhibits significant biological activity in modulating cellular signaling pathways associated with cancer progression and apoptosis. Safingol hydrochloride is primarily utilized in research focused on cancer biology, cardiovascular disease, and neuroprotection, providing valuable insights into PKC-related mechanisms. -
PKCβII Inhibitor
PKCβII Peptide Inhibitor I is a selective inhibitor of Protein Kinase C beta II (PKCβII). This peptide demonstrates significant cardioprotective effects in rat models of ischemia/reperfusion injury, making it a valuable tool in cardiovascular research. Additionally, it has been shown to prevent vascular endothelial dysfunction, highlighting its potential applications in studying vascular health and related pathologies. -
Protein Kinase C Inhibitor/LTD4 Antagonist
LY 170198 is a potent protein kinase C inhibitor and LTD4 antagonist. This compound exhibits significant biological activity relevant to studies on tumor promotion, oncogene activation, and protein phosphorylation. Additionally, it is valuable for investigating feedback mechanisms in signal transduction pathways and cellular responses to growth factors, making it a useful tool for cancer research and related fields. -
PKC Inhibitor
Go 7874 is a protein kinase C (PKC) inhibitor that exhibits neuroprotective effects in models of immune-mediated neurotoxicity. This compound mitigates LPS/IFNg-induced neuronal cell death not through conventional PKC inhibition, but by suppressing the expression of inducible nitric oxide synthase (iNOS), leading to decreased nitric oxide (NO) production. Its unique mechanism makes Go 7874 a valuable tool for studying neuroprotective strategies in inflammatory conditions. -
Akt/ROCK Inhibitor
Akt/ROCK-IN-1 is a potent dual inhibitor targeting Akt and ROCK, exhibiting IC50 values of 0.023 nM and 1.47 nM, respectively. This compound demonstrates significant antitumor activity, particularly in neuroblastoma models. It serves as a valuable tool for research into cancer biology and therapeutic development. -
PKCα Inhibitor
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) is an inhibitor of protein kinase C (PKC)α, demonstrating significant anti-cancer and antioxidant activities. It directly binds to CDK1 and CDK2, leading to the suppression of their activity. Additionally, Desmethylglycitein inhibits PI3K in an ATP-competitive manner, affecting downstream signaling pathways and reducing adipogenesis in 3T3-L1 preadipocytes. Its mechanisms make it a valuable tool for research in cancer biology and metabolic disorders. -
PKC Inhibitor
Bisindolylmaleimide X is a potent protein kinase C (PKC) inhibitor that exhibits cell-penetrating properties. It effectively inhibits the proliferation of CD4 T cells in vitro and shows antagonistic activity against cyclin-dependent kinase 2 (CDK2) with an IC50 of 200 nM. Additionally, Bisindolylmaleimide X suppresses eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. This compound is valuable for studying mechanisms in the immune system and cardiovascular diseases. -
PKA Anchoring Inhibitor
st-Ht31 is a membrane-permeable peptide that inhibits protein kinase A (PKA) anchoring. It effectively induces cholesterol and phospholipid efflux and has been shown to completely reverse foam cell formation in macrophages. This compound offers valuable insights into PKA-related signaling pathways and metabolic health research. -
Myo1s/TGF-β Inhibitor
Pentachloropseudilin is a potent reversible allosteric inhibitor targeting Myo1s (class 1 myosins), exhibiting IC50 values ranging from 1 to 5 μM for mammalian class-1 myosins, while displaying greater than 90 μM for class-2 and class-5 myosins. Additionally, it effectively inhibits transforming growth factor-β (TGF-β) signaling, with an IC50 of 0.1 to 0.2 μM. This compound is valuable for research in cellular signaling pathways and myosin function, contributing to studies in cell motility and tissue remodeling. -
PKC Inhibitor
PKC-iota inhibitor 1 is an inhibitor of protein kinase C-iota (PKC-ι) with an IC50 value of 0.34 μM. This compound demonstrates significant biological activity relevant to cancer research, making it a valuable tool for investigating the role of PKC-ι in tumorigenesis and signal transduction pathways. It is suitable for studies focused on cancer biology and therapeutic interventions targeting PKC-ι. -
PKC Inhibitor
DL-erythro-Dihydrosphingosine is a sphingosine-derived protein kinase C (PKC) inhibitor that functions by directly inhibiting phospholipase A2 (PLA2) activity. This compound also attenuates the function of Bcl-2, a protein that plays a crucial role in regulating apoptosis. Additionally, DL-erythro-Dihydrosphingosine inhibits matrix metalloproteinases (MMPs), which are involved in various cellular processes. Its unique biological activity makes it valuable for research in cancer and inflammatory disease models. -
PKC/HCMV Inhibitor
Bisindolylmaleimide IV is a selective inhibitor of protein kinase C (PKC), exhibiting IC50 values between 0.1 and 0.55 μM. It also demonstrates inhibition of protein kinase A (PKA) with IC50 ranging from 3.1 to 11.8 μM. In addition to its kinase inhibitory properties, Bisindolylmaleimide IV effectively inhibits human cytomegalovirus (HCMV) replication in cell culture, displaying an IC50 of 0.2 μM. This reagent is valuable for research applications focused on signal transduction and viral pathogenesis. -
PKC Inhibitor
Sangivamycin is a nucleoside analog that serves as a potent inhibitor of protein kinase C (PKC) with a Ki value of 10 μM. This compound exhibits significant antiproliferative activity against a diverse range of human cancers, making it a valuable tool for cancer research and therapeutic studies focused on PKC modulation. Its targeted mechanism of action positions Sangivamycin as a promising candidate for further exploration in cancer treatment. -
PKC inhibitor
Ruboxistaurin (LY333531) is a potent, selective inhibitor of Protein Kinase C isozymes, PKC β I(IC50=4.7 nM) and PKC β II (IC50=5.9 nM). -
PKC inhibitor
PKC 412 is a broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms α/β/γ, PDFRβ, VEGFR2, Syk, Flk-1, Flt3, Cdk1/B, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity. -
BMP receptor inhibitor
LDN-212854 is an ALK2-Biased BMP Type I Receptor Kinase Inhibitor. -
δ-protein kinase C (δPKC) inhibitor
Delcasertib (KAI-9803) is a potent and selective δ-protein kinase C (δPKC) inhibitor. -
Smad inhibitor
Kartogenin potently induces differentiation of human mesenchymal stem cells into chondrocytes -
PKC inhibitor
GF 109203X is a potent and selective inhibitor of protein kinase C, selective for the α and β1 isoforms (IC50 values are 0.0084, 0.0180, 0.210, 0.132, and 5.8 μM for α, β1, δ, ε and ζ isoforms respectively). Selective over MLCK, PKG and PKA (IC50 values are 0.6, 4.6, and 33 μM respectively). Potent antagonist at the 5-HT3 receptor (Ki = 29.5 nM). -
PKC inhibitor
Sotrastaurin is a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. -
ROCK inhibitor
Y-33075 dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM. -
PKA, PKG, Casein Kinase I and II inhibitor
A-3 Hydrochloride is an inhibitor of PKA (cAMP-dependent protein kinase, Ki=4.3μM) and cGMP-dependent protein kinase, Ki=3.8μM, PKC (protein kinase C, Ki=47μM), casein kinase I and II, and MLCK (myosin light chain kinase) ( Ki=7.4μM). -
MAPKAP-K2 (MK-2) inhibitor
MK-2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM. -
ROCK inhibitor
Glycyl-H 1152 2HCl is a selective and potent ROCK inhibitor (IC50 values are 0.0118, 2.35, 2.57, 3.26, > 10 and >10 uM for ROCKII, Aurora A, CAMKII, PKG, PKA and PKC respectively.) -
ROCK Inhibitor
HA-1077 inhibits vascular smooth muscle contraction by acting as an intracellular Ca2+ antagonist. -
PKs inhibitor
HA-100 is an isoquinoline compound with an added piperazinylsulfonyl group that acts as an inhibitor of protein kinases (PKs), including PKA, PKC, and PKG (IC50 = 8, 12, and 4 μM, respectively).
